Demant A/S Unsponsored ADR (OTCMKTS:WILYY) Short Interest Down 52.2% in June

Demant A/S Unsponsored ADR (OTCMKTS:WILYY) was the recipient of a significant decline in short interest in the month of June. As of June 15th, there was short interest totaling 970 shares, a decline of 52.2% from the May 31st total of 2,028 shares. Based on an average trading volume of 354 shares, the short-interest ratio is presently 2.7 days. Currently, 0.0% of the shares of the company are sold short.

Analysts Set New Price Targets

WILYY has been the subject of a number of research reports. Jefferies Financial Group upgraded Demant A/S from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, March 18th. Morgan Stanley upgraded Demant A/S from an “equal weight” rating to an “overweight” rating in a research report on Tuesday, June 23rd. One research analyst has rated the stock with a Strong Buy rating and one has given a Buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Strong Buy”.

Demant A/S Stock Performance

Shares of WILYY stock opened at $19.25 on Tuesday. Demant A/S has a 52-week low of $13.45 and a 52-week high of $21.30. The company has a debt-to-equity ratio of 1.65, a quick ratio of 1.00 and a current ratio of 1.36. The firm has a fifty day moving average of $18.41 and a 200-day moving average of $16.46.

Demant A/S Company Profile

Demant A/S is a Denmark-based global hearing health care company specializing in the development, manufacture and distribution of hearing solutions and audiological diagnostic instruments. The company’s flagship brands include Oticon, Bernafon and Sonic, which offer a range of hearing aids designed to address various levels of hearing loss. In addition to personal hearing devices, Demant provides diagnostic equipment such as audiometers and tympanometers, supporting hearing care professionals in accurate assessment and fitting of hearing solutions.

Beyond hearing aids and diagnostics, Demant’s product portfolio extends to hearing implants—cochlear and bone-anchored systems—through its Oticon Medical division.